John Houghton
Institute of Cancer Research
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by John Houghton.
Journal of Enzyme Inhibition | 1992
John H. Davies; Robert J. Shearer; Martin G. Rowlands; Grace K. Poon; John Houghton; Michael Jarman; Mitch Dowsett
The steroidal aromatase inhibitor, 4-hydroxyandrost-4-ene-3,17-dione (4OHA) and its metabolites, 4-hydroxytestosterone (4OHT), 3 beta,17-dihydroxy-5 alpha-androstan-4-one (metabolite A) and 3 alpha, 17-dihydroxy-5 beta-androstan-4-one (metabolite B) were evaluated as inhibitors of the human prostatic 5 alpha-reductase enzyme and for binding to the rat prostatic androgen receptor. 4OHA and 4OHT were weak inhibitors of 5 alpha-reductase with IC50 values of 15-29 microM. Metabolites A and B had no significant inhibitory activity. 4OHA and metabolites A and B bound weakly to the androgen receptor. The binding affinities (RBA) relative to mibolerone (RBA = 100) were 0.085, 0.485 and 0.016, respectively. However, 4OHT (RBA = 75) was a more potent binder than the endogenous androgen 5 alpha-dihydrotestosterone (RBA = 66). The ability of these metabolites, in particular 4OHT, to bind to the androgen receptor may explain the in vivo androgenic activity of 4OHA.
Bioorganic & Medicinal Chemistry Letters | 1995
Ian R. Hardcastle; Martin G. Rowlands; John Houghton; Michael Jarman
Abstract 4′-substituted analogues of the antiestrogen idoxifene have been prepared. All the compounds were assayed for antagonism of calmodulin dependent c-AMP phosphodiesterase and for binding to rat uterine estrogen receptor. The 4′-amino compound was the most potent antiestrogen (RBA = 47) whilst retaining a similar calmodulin antagonism to idoxifene.
Biochemical Pharmacology | 1988
Alison Seago; Michael H. Baker; John Houghton; Michael Jarman; Chui-Sheung Leung; Martin G. Rowlands
A homologous series of 1-n-alkyl-derivatives of aminoglutethimide (AG) has been synthesised and tested for inhibitory activity towards the cholesterol side chain cleavage enzyme (desmolase) from bovine adrenals and human placental aromatase in an attempt to find a selective aromatase inhibitor. Activity against desmolase declined from an IC50 value of 30 microM for the parent drug to 220 microM for the n-propyl derivative but increased again thereafter. Against aromatase, activity was least for the methyl and ethyl derivatives and highest (IC50 = 1.6 microM) for the hexyl and octyl analogues. The optimal ratio IC50 (desmolase):IC50 aromatase of 44 was found for the n-propyl derivative, which was therefore selected for preliminary metabolism studies using rat and mouse liver microsomes and hepatocytes and in these species in vivo. There were parallels with AG, most notably in the analogous formation from the n-propyl derivative of an arylhydroxylamine in the mouse.
Journal of Enzyme Inhibition | 1994
Michael Jarman; S. Elaine Barrie; John Houghton; Martin G. Rowlands; John Mann; Margret Haase-Held; Maria Hatzis
AbstractSome 4–fluorinated analogues of 3-oxo-δ4 steroids and 4-cyano derivatives of progesterone and androstenedione were evaluated as inhibitors of steroid 5α-reductase activity. Inhibitors of this enzyme may be useful in treating prostatic cancer. 4-Fluoroandrostenedione was a modest inhibitor of the rat enzyme (IC50 = 4.08 μM), while 4-cyanoprogesterone was a potent inhibitor of both the rat and human enzymes (IC50 values = 0.045 μM and 0.050 μM respectively). These two steroids were tested in vivo for activity against androgen sensitive organs in WHT mice. 4-Fluoroandrostenedione caused increases in organ weights, suggesting it is an androgen agonist, while the 4-cyano compound displayed modest androgen ablation. Therefore substitutions at the 4-position may produce compounds of therapeutic use in treating prostate cancer.
Journal of Medicinal Chemistry | 1995
Martin G. Rowlands; S. E. Barrie; F. C. Y. Chan; John Houghton; Michael Jarman; Raymond McCague; Gerard Andrew Potter
Journal of Medicinal Chemistry | 1990
Raymond McCague; Martin G. Rowlands; S. E. Barrie; John Houghton
Journal of Medicinal Chemistry | 1996
F. C. Y. Chan; Gerard Andrew Potter; S. E. Barrie; B. P. Haynes; Martin G. Rowlands; John Houghton; Michael Jarman
Journal of Medicinal Chemistry | 1995
Ian R. Hardcastle; Martin G. Rowlands; John Houghton; Iris B. Parr; Gerard Andrew Potter; Michael Jarman; Karen J. Edwards; Charles A. Laughton; John O. Trent; Stephen Neidle
Journal of Medicinal Chemistry | 1990
Michael Jarman; S. E. Barrie; Deadman Jj; John Houghton; Raymond McCague; Martin G. Rowlands
Journal of Medicinal Chemistry | 1996
Ian R. Hardcastle; Martin G. Rowlands; Grimshaw Rm; John Houghton; Michael Jarman